Vivek Naranbhai (MBCHB, PhD, DPhil) is an Associate Professor and Head of the Laboratory of Translational Immunology at Monash University. He is a practicing oncologist (trained at the MGH-DFCI in Boston, USA) and has PhD and postdoctoral training in immunology virology and cancer biology. His lab works on the biology of antigen presentation and recognition.

He has over 100 career publications (Field Weighted Citation Impact score of 9.85, h-index 40) including Cell (4), Science (1), The Lancet (1), Nature Comms (2), Journal of Clinical Oncology (1), Cancer Cell (1) and Lancet Oncology (1).

Some of his key discoveries include inflammation as a driver of HIV infection, establishing the International Tuberculosis Host Genetics Consortium (ITHGC), defining the genetic regulation of gene expression in neutrophils, described how components of antigen presentation machinery mediate activating and inhibitory signalling and described several mechanisms by which genetic variation affects cancer immunotherapy outcomes. He also led many of the first COVID-19 sero-epidemiology studies, including the largest cohort study in patients with cancer, providing key insights into how neutralizing antibodies and T-cells mediate cross strain protection and effecting policy decisions on vaccine selection, timing, and development. He is involved in creation of early companies developing immunotherapeutics via roles with venture capital groups.